MarginsXMarginsX
Home › Markets › Health Care › CRSP

CRISPR Therapeutics AG Common Shares (CRSP)

CRSP trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$40.37
-4.43% on the day
Market cap
$3.9B
Mid cap
Revenue · 2025
$3.5M
-90.6% on 2024
Net income · 2025
-$581.6M
-16569.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/0001193125-26-048957-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCRSP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountrySwitzerland
IPO year2016
SEC CIK0001674416
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inSwitzerland

Financials · 2025

LineValue
Revenue$3.5M
Net income-$581.6M
Operating income-$664.6M
Net margin-16569.8%
Operating margin-18933.6%
Revenue growth-90.6%
Cash$347.6M
Total assets$2.3B
P/E (computed)Net income was not positive
P/S (computed)1115.6×

Warning signs

Cash runway
6.2 months
$192.0M cash at September 30, 2026
Share count, 1 year
+1.8%
2025-11-06 to 2026-10-30 · +22.1% over 3 years
Going-concern doubt
No
10-Q filed November 2, 2026
Insider net buying, 12 months
-$18.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-02
Cash and burn$192.0M cash; operating cash flow -$93.7M a quarter.Report 2026-09-30
Shares outstanding97,000,813 (2026-10-30); 95,300,233 a year earlier; 79,432,446 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-04
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $18.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$12.7M-$111.4M-$89.7M$192.0M$586.9M$25.2M10-Q 2026-11-02
Q2 2026
2026-06-30
$10.2M-$91.2M-$83.5M$291.3M$586.2M$13.4M10-Q 2026-08-03
Q1 2026
2026-03-31
$1.5M-$122.9M-$108.9M$423.3M$585.5M$4.1M10-Q 2026-05-04
Q4 2025
2025-12-31
$864K-$130.6M-$92.6M$347.6M$0$3.5M10-K 2026-02-12
Q3 2025
2025-09-30
$889K-$106.4M-$84.6M$286.5MNo debt tags$38.3M10-Q 2026-11-02
Q2 2025
2025-06-30
$892K-$208.5M-$113.9M$193.6MNo debt tags$38.0M10-Q 2026-08-03
Q1 2025
2025-03-31
$865K-$136.0M-$53.9M$235.2MNo debt tags$37.7M10-Q 2026-05-04
Q4 2024
2024-12-31
$35.7M-$37.3M-$50.0M$298.3MNo debt tags$37.3M10-K 2026-02-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-10-15
Latest annual report10-K2026-02-12
Latest quarterly / interim10-Q2026-11-02
Latest current report8-K2026-11-02
Latest proxyDEFA14A2026-04-21

Source: SEC EDGAR submissions feed, 885 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-15.6%
1 month-15.7%
3 months-21.8%
Year to date-19.5%
1 year-17.4%
From 52-week high-31.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
TARSTarsus Pharmaceuticals Inc.$78.68-1.99%$3.9B
RLAYRelay Therapeutics Inc.$17.27-4.53%$3.8B
IOVAIovance Biotherapeutics Inc.$7.55-2.71%$3.5B
ADPTAdaptive Biotechnologies Corporation$27.87-4.03%$4.5B
ADMAADMA Biologics Inc$13.47-1.54%$3.0B
VCELVericel Corporation$57.48+0.91%$2.9B
DNLIDenali Therapeutics Inc.$18.08-3.52%$2.9B
SRRKScholar Rock Holding Corporation$44.54+3.09%$5.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier